Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

N4 Pharma Plc (N4P)

Price 0.525p on 26-12-2024 at 05:12:28
Change 0.00p 0%
Buy 0.55p
Sell 0.50p
Buy / Sell N4P Shares
Last Trade: -
Day's Volume: 0
Last Close: 0.525p
Open: 0.00p
ISIN: GB00BYW8QM32
Day's Range 0.00p - 0.00p
52wk Range: 0.412p - 1.30p
Market Capitalisation: £2m
VWAP: 0.00p
Shares in Issue: 395m

Recent Trades History N4 Pharma Plc (N4P)

Buy/Sell Volume Trade Prc Trade Type Trade Time

Share Price History for N4 Pharma Plc

Time period:
to
Date Open High Low Close Volume

Share News for N4 Pharma Plc

AIM WINNERS & LOSERS: Velocity Composites expects to beat market view

12th Dec 2024 10:40

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday. Read More

AIM WINNERS & LOSERS: Biome warns on revenue; legal blow for LCM

4th Dec 2024 10:57

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Wednesday. Read More

EARNINGS: Metals One advances Black Schist, N4 generates revenue

24th Sep 2024 15:01

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

IN BRIEF: N4 Pharma celebrates chemistry work update on Nuvec

20th Aug 2024 11:52

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of nanoparticle technology Nuvec - Notes SRI International has successfully completed the chemistry work and shown that a fox three molecular guidance system can be added to Nuvec without altering its loading capability. Chief Executive Nigel Theobald says: "This is an exciting development for us as it clearly shows that Nuvec is capable of targeting specific cells via the addition of a relevant ligand, something the industry is actively looking for. We will now start working on a combined marketing pitch deck allowing SRI and N4 Pharma to present this data and its implications to major pharma and biotech players that need a targeting delivery system for their nucleic acid programs." N4 Pharma says the next step is to show that small interfering RNA still retains its functionality in the target cell. Read More

AIM WINNERS & LOSERS: Shuka Minerals down on CLN drawdown

20th Aug 2024 10:24

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday. Read More

FTSE 100 Latest
Value8,136.99
Change0.00

Login to your account

Forgot Password?

Not Registered